Treatment of refractory sclerodermatous chronic graft-versus-host disease with intravenous lidocaine infusions

[1] Inamoto Y(2013)Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease Blood 121 5098-5103

[2] Storer BE(1977)[Some little-known conservative methods of treatment of Raynaud's syndrome] Phlebologie 30 199-204

[3] Petersdorf EW(1994)Local anesthetic lidocaine inhibits the effect of granulocyte colony-stimulating factor on human neutrophil functions Exp Hematol 22 460-466

[4] Nelson JL(2001)Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion Bone Marrow Transplant 28 97-99

[5] Lee SJ(2008)Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease Biol Blood Marrow Transplant 14 1380-1384

[6] Carpenter PA(2013)More than skin deep? Emerging therapies for chronic cutaneous GVHD Bone Marrow Transplant 48 323-337

[7] Van Der Molen HR(2012)Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD Blood 120 5089-5090

[8] Balmus K(2008)Lidocaine down-regulates nuclear factor-kappaB signalling and inhibits cytokine production and T cell proliferation Clin Exp Immunol 152 320-327

[9] Ohsaka A(2013)Possible involvement of cytokines, chemokines and chemokine receptors in the initiation and progression of chronic GVHD Bone Marrow Transplant 48 115-123

[10] Saionji K(2011)Lidocaine for systemic sclerosis: a double-blind randomized clinical trial Orphanet J Rare Dis 6 5.-undefined

[1] Inamoto Y(2013)Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease Blood 121 5098-5103

[2] Storer BE(1977)[Some little-known conservative methods of treatment of Raynaud's syndrome] Phlebologie 30 199-204

[3] Petersdorf EW(1994)Local anesthetic lidocaine inhibits the effect of granulocyte colony-stimulating factor on human neutrophil functions Exp Hematol 22 460-466

[4] Nelson JL(2001)Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion Bone Marrow Transplant 28 97-99

[5] Lee SJ(2008)Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease Biol Blood Marrow Transplant 14 1380-1384

[6] Carpenter PA(2013)More than skin deep? Emerging therapies for chronic cutaneous GVHD Bone Marrow Transplant 48 323-337

[7] Van Der Molen HR(2012)Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD Blood 120 5089-5090

[8] Balmus K(2008)Lidocaine down-regulates nuclear factor-kappaB signalling and inhibits cytokine production and T cell proliferation Clin Exp Immunol 152 320-327

[9] Ohsaka A(2013)Possible involvement of cytokines, chemokines and chemokine receptors in the initiation and progression of chronic GVHD Bone Marrow Transplant 48 115-123

[10] Saionji K(2011)Lidocaine for systemic sclerosis: a double-blind randomized clinical trial Orphanet J Rare Dis 6 5.-undefined